ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.
Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
This clinical trial aims to investigate whether periods of time where the mechanistic target of Rapamycin (mTOR) pathway is activated via exercise, combined with alternate periods of time where mTOR is inhibited using Sirolimus (Rapamycin), will result in greater muscle performance in older adults compared with just exercise alone.